Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

BioLife Solutions, Inc.

BLFSNASDAQ
Healthcare
Medical - Instruments & Supplies
$19.08
$0.72(3.92%)
U.S. Market opens in 17h 10m

BioLife Solutions, Inc. Fundamental Analysis

BioLife Solutions, Inc. (BLFS) shows weak financial fundamentals with a PE ratio of -71.87, profit margin of -12.61%, and ROE of -3.40%. The company generates $0.1B in annual revenue with weak year-over-year growth of -42.59%.

Key Strengths

Cash Position16.82%
PEG Ratio0.21
Current Ratio5.23

Areas of Concern

ROE-3.40%
Operating Margin-12.61%
We analyze BLFS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -25.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-25.5/100

We analyze BLFS's fundamental strength across five key dimensions:

Efficiency Score

Weak

BLFS struggles to generate sufficient returns from assets.

ROA > 10%
-2.99%

Valuation Score

Excellent

BLFS trades at attractive valuation levels.

PE < 25
-71.87
PEG Ratio < 2
0.21

Growth Score

Moderate

BLFS shows steady but slowing expansion.

Revenue Growth > 5%
-42.59%
EPS Growth > 10%
71.05%

Financial Health Score

Excellent

BLFS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.05
Current Ratio > 1
5.23

Profitability Score

Weak

BLFS struggles to sustain strong margins.

ROE > 15%
-340.39%
Net Margin ≥ 15%
-12.61%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BLFS Expensive or Cheap?

P/E Ratio

BLFS trades at -71.87 times earnings. This suggests potential undervaluation.

-71.87

PEG Ratio

When adjusting for growth, BLFS's PEG of 0.21 indicates potential undervaluation.

0.21

Price to Book

The market values BioLife Solutions, Inc. at 2.34 times its book value. This may indicate undervaluation.

2.34

EV/EBITDA

Enterprise value stands at -111.48 times EBITDA. This is generally considered low.

-111.48

How Well Does BLFS Make Money?

Net Profit Margin

For every $100 in sales, BioLife Solutions, Inc. keeps $-12.61 as profit after all expenses.

-12.61%

Operating Margin

Core operations generate -12.61 in profit for every $100 in revenue, before interest and taxes.

-12.61%

ROE

Management delivers $-3.40 in profit for every $100 of shareholder equity.

-3.40%

ROA

BioLife Solutions, Inc. generates $-2.99 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.99%

Following the Money - Real Cash Generation

Operating Cash Flow

BioLife Solutions, Inc. produces operating cash flow of $20.35M, showing steady but balanced cash generation.

$20.35M

Free Cash Flow

BioLife Solutions, Inc. generates strong free cash flow of $12.95M, providing ample flexibility for dividends, buybacks, or growth.

$12.95M

FCF Per Share

Each share generates $0.27 in free cash annually.

$0.27

FCF Yield

BLFS converts 1.45% of its market value into free cash.

1.45%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-71.87

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.21

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.34

vs 25 benchmark

P/S Ratio

Price to sales ratio

9.14

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.05

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.23

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.03

vs 25 benchmark

ROA

Return on assets percentage

-0.03

vs 25 benchmark

ROCE

Return on capital employed

-0.03

vs 25 benchmark

How BLFS Stacks Against Its Sector Peers

MetricBLFS ValueSector AveragePerformance
P/E Ratio-71.8728.25 Better (Cheaper)
ROE-3.40%780.00% Weak
Net Margin-12.61%-20122.00% (disorted) Weak
Debt/Equity0.050.30 Strong (Low Leverage)
Current Ratio5.234.66 Strong Liquidity
ROA-2.99%-14687.00% (disorted) Weak

BLFS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews BioLife Solutions, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

26.95%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-414.57%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

193.61%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ